

## **Short Bio**

Dr. Bart Barlogie recently joined the Icahn School of Medicine at Mt. Sinai in New York as Director of Myeloma Research. He had previously headed the Myeloma Institute at the University of Arkansas for Medical Sciences, which he founded 26 years ago. Under his leadership, multiple myeloma has become a curable disease when applying his Total Therapy approach – meaning using all active agents upfront, followed by tandem melphalan-based autotransplants, consolidation chemotherapy and maintenance. He is now focusing his attention on the 15% of patients presenting with genomically defined high-risk MM, by applying metronomically scheduled chemotherapy and targeting mutations.